Vildagliptin

證據等級: L5

預測適應症: 10 個

Vildagliptin: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome

One-Sentence Summary

Vildagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor originally developed for type 2 diabetes mellitus (T2DM), improving glycemic control by prolonging endogenous GLP-1/GIP activity. The TxGNN model's top-ranked prediction is Focal Stiff Limb Syndrome, with a prediction score of 99.88%, but this candidate currently has 0 clinical trials and 0 supporting publications, and the evidence pack itself flags no plausible mechanistic link — this is a pure model-score hit, not a substantiated repurposing hypothesis.

Quick Overview

Item	Content
Original Indication	Type 2 Diabetes Mellitus (derived from literature within the evidence pack; not formally recorded in regulatory data as the drug is unmarketed in Germany)
Predicted New Indication	Focal Stiff Limb Syndrome
TxGNN Prediction Score	99.88%
Evidence Level	L5
Germany Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is officially marked as a data gap (DrugBank query pending). Based on information embedded in the accompanying literature and trial evidence, vildagliptin is known to inhibit DPP-4, thereby extending the half-life of endogenous GLP-1 and GIP, enhancing glucose-dependent insulin secretion, and suppressing inappropriate glucagon release — its efficacy in T2DM is well established in this class.

However, for the top-ranked candidate, Focal Stiff Limb Syndrome, no plausible mechanistic bridge exists. Stiff limb/stiff person syndrome is an autoimmune neurological disorder driven primarily by anti-GAD65 antibodies and impaired GABAergic inhibitory transmission — a pathophysiology entirely unrelated to incretin/glucose signaling. The evidence pack's own rationale explicitly states: "無可辨識之機轉關聯…此為TxGNN純預測分數，缺乏任何生物學支持論述" (no identifiable mechanistic link; this is a pure TxGNN prediction score without biological support). The same holds for TxGNN's other top-5 hits (classic stiff person syndrome, thiamine-responsive dysfunction syndrome, opsismodysplasia) — all are rare, structurally or genetically driven diseases with no known DPP-4 connection.

Given the very high raw score but complete absence of corroborating evidence, this prediction should be treated as a statistical artifact of the knowledge-graph embedding rather than a credible repurposing hypothesis at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Germany Market Information

Vildagliptin is currently not marketed in Germany (未上市) under this evidence pack, with 0 registered authorizations. No product/license records are available for this candidate.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all currently marked as data gaps — TFDA label retrieval is a blocking item, see Conclusion.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (Focal Stiff Limb Syndrome) has Evidence Level L5 — a model score with zero clinical trials, zero literature, and no identifiable mechanistic rationale. Combined with the drug's unmarketed status in Germany and missing MOA/label data (DG001 blocking, DG002 high severity), there is no basis to advance this indication beyond exploratory screening.

To proceed, the following is needed:

TFDA/official label retrieval (warnings, contraindications) — currently blocking S1 safety screening
Confirmed DrugBank MOA data
Any preclinical or mechanistic rationale connecting DPP-4/incretin pathways to autoimmune stiff-person-spectrum disease, before further evaluation is justified

Additional Note — Alternative Signal Worth Tracking: Among this drug's 10 TxGNN-predicted indications, Type 1 Diabetes Mellitus (rank 10, score 99.37%) stands out as the only candidate with substantive evidence: Evidence Level L2, including a completed Phase 2 RCT directly testing rapamycin + vildagliptin for β-cell function recovery in long-standing T1D (NCT02803892; concordant RCT publication PMID 33124663), plus mechanistic RCT evidence on glucagon counter-regulation in T1D (PMID 22855332). This is mechanistically coherent (incretin-mediated β-cell preservation as adjunct, not insulin replacement) and is a more defensible candidate for a "Research Question" stage evaluation than the top-ranked stiff-limb-syndrome hit, though most of its 40+ listed trials are T2DM noise and would need individual re-grading before use.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.